• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Croatia Pharmaceuticals and Healthcare Report Q4 2012 - Product Image

Croatia Pharmaceuticals and Healthcare Report Q4 2012

  • ID: 2204670
  • September 2012
  • Region: Croatia
  • 84 pages
  • Business Monitor International

The Croatia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Croatia's pharmaceuticals and healthcare industry.

Executive Summary

BMI View: Croatian pharmaceutical market will continue to be weakened by economic recession in 2012 combined with cost-containment measures that will affect public sector funding. Generally speaking, the performance of Croatia’s pharmaceutical, healthcare and medical device markets is increasingly tied to the country’s challenging economic outlook. At best, Croatia’s pharmaceutical market will continue to represent a modest prospect for foreign companies. despite the country’s gradual convergence with EU legislation and standards, as part of its accession process.

Headline Expenditure Projections:

- Pharmaceuticals: HRK7.16bn (US$1.34bn) in 2011 to HRK7.09bn (US$1.30bn) in 2012;
-1.0% in local currency and -3.0% in US dollar terms. Forecast up slightly from Q312 due to analyst intervention.

- Healthcare: HRK26.23bn READ MORE >

Executive Summary 5

SWOT Analysis 7

Croatia Pharmaceuticals Industry SWOT 7

Croatia Political SWOT 8

Croatia Economic SWOT 8

Croatia Business Environment SWOT 8

Pharmaceutical Business Environment Ratings 10
Table: Central And Eastern Europe Risk/Reward Ratings, Q412 10

Rewards 11

Risks 12

Croatia – Market Summary 14

Regulatory Regime 16

Pharmaceutical Advertising 17

Intellectual Property Regime 18

Pricing Regime 19

Reimbursement Regime 20

OTC Regulations 22

Industry Trends And Developments 23

Epidemiology 23

Healthcare Provision 24

Healthcare Expenditure 24
Table: Reimbursed Drug Expenditure By HZZO (HRK) - Equivalent to Final Consumer Prices 25
Table: State Budget for Healthcare (HRKbn) 25

Healthcare Reform 26

Clinical Trials 27

Medical Devices 27

Industry Forecast Scenario 29

Overall Market Forecast 29
Table: Pharmaceutical Sales Indicators 2008-2016 30
Table: Reimbursed Drug Expenditure By HZZO (HRK) - Equivalent to Final Consumer Prices 31

Key Growth Factors – Industry 32
Table: Healthcare Expenditure Indicators 2008-2016 33
Table: Healthcare Governmental Indicators 2008-2016 33
Table: Healthcare Private Indicators 2008-2016 34

Key Growth Factors – Macroeconomic 35
Table: Croatia Economic Activity, 2011-2016 36

Prescription Drug Market Forecast 37
Table: Prescription Drug Sales Indicators 2008-2016 38

Patented Drug Market Forecast 39
Table: Patented Drug Market Indicators 2008-2016 40

Generic Drug Market Forecast 41
Table: Generic Drug Sales Indicators 2008-2016 42

OTC Medicine Market Forecast 42
Table: OTC Medicine Sales Indicators 2008-2016 44

Croatia Pharmaceuticals & Healthcare Report Q4 2012

© Business Monitor International Ltd

Page 4

Pharmaceutical Trade Forecast 44
Table: Exports and Imports Indicators 2008-2016 45

Medical Device Market Forecast 46
Table: Medical Devices Sales Indicators 2008-2016 47

Other Healthcare Forecasts 47

Key Risks To our Forecast Scenario 48

Competitive Landscape 50

Pharmaceutical Industry 50
Table: Top-10 Medicines By Value Sales 51

Domestic Pharmaceutical Industry 52
Table: Croatian Pharmaceutical Manufacturers 53

Foreign Pharmaceutical Industry 54

Company Activity 54

Pharmaceutical Wholesale 55

Pharmaceutical Retail 56

Company Profiles 58

Local Company Profiles 58

PLIVA (Teva Pharmaceuticals) 58

Belupo 61

Jadran Galenski Laboratorij 64

Foreign Company Profiles 66

GlaxoSmithKline 66

Pfizer 68

Sanofi 69

Novartis 70

Merck & Co 71

Krka 72

Demographic Data 74
Table: Population By Age Group, 1990-2020 (‘000) 75
Table: Population By Age Group, 1990-2020 (% of total) 75
Table: Key Population Ratios, 1990-2020 76
Table: Rural/Urban Population Split, 1990-2020 76

Glossary 78

BMI Methodology 80

How We Generate Our Pharmaceutical Industry Forecasts 80

Risk/Reward Ratings Methodology 81

Ratings Overview 81
Table: Pharmaceutical Business Environment Indicators 82

Weighting 83
Table: Weighting Of Components 83

PLIVA (Teva Pharmaceuticals) , Belupo , Jadran Galenski Laboratorij , GlaxoSmithKline , Pfizer, Sanofi , Novartis , Merck & Co , Krka ,

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos